

## 120172

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: WO 98/15265 (11) International Publication Number: A61K 9/52, 9/48 **A1** (43) International Publication Date: 16 April 1998 (16.04.98)

PCT/GB97/02726 (21) International Application Number:

(22) International Filing Date: 6 October 1997 (06.10.97)

(30) Priority Data:

9620709.7

4 October 1996 (04.10.96) GB

(71) Applicant (for all designated States except US): DANBIOSYST UK LIMITED [GB/GB]; Albert Einstein Centre, Highfields Science Park, Nottingham NG7 2TN (GB).

(72) Inventor; and

- (75) Inventor/Applicant (for US only): WATTS, Peter, James [GB/GB]; Flat 2, 47 Highfield Road, West Bridgford, Nottingham NG2 6DR (GB).
- (74) Agent: BASSETT, Richard; Eric Potter Clarkson, St. Mary's Court, St. Mary's Gate, Nottingham NG1 1LE (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

## Published


With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: COLONIC DELIVERY OF WEAK ACID DRUGS

## (57) Abstract

There is provided controlled release formulation including an inner core comprising, or coated with, a drug, which drug possesses (a) a free acid group which can be converted into an alkali metal salt and (b) a pKa in the range 2.0 to 9.0, which inner core is subsequently coated with a rate-controlling membrane drug determines that release, wherein the drug is present as a salt that displays higher solubility at pH 4.5 to 8.0 than the corresponding compound containing a free acid group.



100 2